Simply Wall St.
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
📊
AI Sentiment
Positive
7/10
- Home
- NVCT
NVCT
Nuvectis Pharma Inc.
as of 12-11-2025 3:36pm EST
$7.53
+$0.28
+3.79%
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Chart Type:
Time Range:
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | FORT LEE |
| Market Cap: | 171.9M | IPO Year: | 2022 |
| Target Price: | $15.33 | AVG Volume (30 days): | 91.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.44 - $11.52 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered NVCT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 63.19%
63.19%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nuvectis Pharma Inc. (NVCT)
BENTSUR RON
Buy
Chairman & CEO
NVCT Nov 5, 2025
Avg Cost/Share
$5.72
Shares
5,000
Total Value
$28,600.00
Owned After
3,525,924
SEC Form 4
Kaplan Matthew L.
Buy
Director
NVCT Nov 5, 2025
Avg Cost/Share
$5.84
Shares
11,000
Total Value
$64,240.00
Owned After
124,760
SEC Form 4
Sanchez Juan
Buy
Director
NVCT Nov 5, 2025
Avg Cost/Share
$5.79
Shares
13,000
Total Value
$75,270.00
Owned After
78,150
SEC Form 4
Mosseri Marlio Charles
Buy
10% Owner
NVCT Oct 27, 2025
Avg Cost/Share
$6.28
Shares
72,836
Total Value
$457,410.08
Owned After
3,136,576
SEC Form 4
Mosseri Marlio Charles
Buy
10% Owner
NVCT Oct 24, 2025
Avg Cost/Share
$6.15
Shares
35,034
Total Value
$215,459.10
Owned After
3,136,576
SEC Form 4
Mosseri Marlio Charles
Buy
10% Owner
NVCT Oct 23, 2025
Avg Cost/Share
$6.06
Shares
46,900
Total Value
$284,214.00
Owned After
3,136,576
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BENTSUR RON | NVCT | Chairman & CEO | Nov 5, 2025 | Buy | $5.72 | 5,000 | $28,600.00 | 3,525,924 | |
| Kaplan Matthew L. | NVCT | Director | Nov 5, 2025 | Buy | $5.84 | 11,000 | $64,240.00 | 124,760 | |
| Sanchez Juan | NVCT | Director | Nov 5, 2025 | Buy | $5.79 | 13,000 | $75,270.00 | 78,150 | |
| Mosseri Marlio Charles | NVCT | 10% Owner | Oct 27, 2025 | Buy | $6.28 | 72,836 | $457,410.08 | 3,136,576 | |
| Mosseri Marlio Charles | NVCT | 10% Owner | Oct 24, 2025 | Buy | $6.15 | 35,034 | $215,459.10 | 3,136,576 | |
| Mosseri Marlio Charles | NVCT | 10% Owner | Oct 23, 2025 | Buy | $6.06 | 46,900 | $284,214.00 | 3,136,576 |
Latest Nuvectis Pharma Inc. News
NVCT Breaking Stock News: Dive into NVCT Ticker-Specific Updates for Smart Investing
Compare NVCT vs Leading Stocks
See how NVCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVCT Nuvectis Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.